Management of relapsed-refractory diffuse large B cell lymphoma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Relapsed-Refractory Diffuse Large B Cell Lymphoma (RR DLBCL) affects one-third of DLBCL patients, posing significant morbidity and mortality risks.
• Current management strategies for RR DLBCL present ongoing challenges for hemato-oncologists.

Purpose of the Study:

• To review pertinent issues in the management of Relapsed-Refractory Diffuse Large B Cell Lymphoma.
• To discuss the impact of rituximab on treatment outcomes in RR DLBCL.

Main Methods:

• Review of current literature and standard treatment protocols for RR DLBCL.
• Discussion of salvage chemotherapy regimens and autologous stem cell transplantation.

Main Results:

• Salvage high-dose chemotherapy with autologous stem cell transplantation is the standard for chemosensitive relapses.
• The incorporation of rituximab into salvage regimens has demonstrated improved outcomes for RR DLBCL patients.

Conclusions:

• Optimizing salvage regimens for RR DLBCL remains an active area of research.
• Rituximab represents a key advancement in improving treatment efficacy for RR DLBCL.